Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444742 · ClinicalTrials.gov registry record · Phase 2
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT01444742: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01444742 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01444742, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if clofarabine when given in combination with cytarabine can help to control myelodysplastic syndrome (MDS) after the disease could not be controlled with standard therapy. The safety of this treatment will also be studied. Clofarabine is designed to interfere with the growth and development of cancer cells. Cytarabine is designed to insert itself into DNA (the genetic material of cells) of cancer cells and stop the DNA from repairing itself.
Interventions
- DRUG Cytarabine
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2011-11-16 |
| Est. Completion | 2017-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01444742
The ClinicalTrials.gov registry entry for NCT01444742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT01444742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01444742 about?
NCT01444742 is a clinical study titled "Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if clofarabine when given in combination with cytarabine can help to control myelodysplastic syndrome (MDS) after the disease could not be controlled with standard therapy. The safety of this treatment will also be studied. Clofarabine is designe...
What is the current status of trial NCT01444742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2011-11-16. Estimated completion is 2017-01-29.
What interventions are being tested in trial NCT01444742?
The interventions under investigation include: Cytarabine (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT01444742?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.